Back to top

Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study

Prelude Therapeutics, Inc. (($PRLD)) announced an update on their ongoing clinical study. Prelude Therapeutics, Inc. has launched a Phase 2 clinica...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Prelude Therapeutics Incorporated (PRLD)